

In the Claims

1-71 (canceled).

72 (currently amended). An isolated polypeptide ~~selected from the group consisting of~~ comprising:

- a) SEQ ID NO:34; and/or
- b) a fusion protein comprising SEQ ID NO: 34 and a heterologous sequence.

73 (previously presented). The isolated polypeptide according to claim 72, wherein said polypeptide comprises SEQ ID NO: 34.

74 (previously presented). The isolated polypeptide according to claim 72, wherein said polypeptide comprises a fusion protein comprising SEQ ID NO: 34 and a heterologous sequence.

75 (previously presented). The isolated polypeptide according to claim 74, wherein said fusion protein comprises SEQ ID NO: 34 and said heterologous sequence comprises an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal sequence or a histidine tag.

76 (previously presented). The isolated polypeptide according to claim 75, wherein said heterologous sequence comprises an extracellular domain of a membrane-bound protein.

77 (previously presented). The isolated polypeptide according to claim 75, wherein said heterologous sequence comprises an immunoglobulin constant region.

78 (previously presented). The isolated polypeptide according to claim 75, wherein said heterologous sequence comprises a multimerization domain.

79 (previously presented). The isolated polypeptide according to claim 75, wherein said heterologous sequence comprises a signal sequence.

80 (previously presented). The isolated polypeptide according to claim 75, wherein said heterologous sequence comprises a histidine tag.

81 (currently amended): A composition comprising a pharmaceutically acceptable excipient and a polypeptide ~~selected from the group consisting of~~ comprising:

- a) SEQ ID NO:34; ~~and or~~
- b) a fusion protein comprising SEQ ID NO: 34 and a heterologous sequence.

82 (previously presented). The composition according to claim 81, wherein said polypeptide comprises SEQ ID NO: 34.

83 (previously presented). The composition according to claim 81, wherein said polypeptide comprises a fusion protein comprising SEQ ID NO: 34 and a heterologous sequence.

84 (previously presented). The composition according to claim 81, wherein said fusion protein comprises SEQ ID NO: 34 and said heterologous sequence comprises an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal sequence or a histidine tag.

85 (previously presented). The composition according to claim 84, wherein said heterologous sequence comprises an extracellular domain of a membrane-bound protein.

86 (previously presented). The composition according to claim 84, wherein said heterologous sequence comprises an immunoglobulin constant region.

87 (previously presented). The composition according to claim 84, wherein said heterologous sequence comprises a multimerization domain.

88 (previously presented). The composition according to claim 84, wherein said heterologous sequence comprises a signal sequence.

89 (previously presented). The composition according to claim 84, wherein said heterologous sequence comprises a histidine tag.